Amneal Pharmaceuticals, Inc. (AMRX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Amniel Pharmaceuticals First Quarter 2025 Earnings Call. I'd now like to turn the call over to Amniel's Head of Investor Relations, Tony DiMaio. Good morning, and thank you for joining Amniel Pharmaceuticals First Quarter 2025 Earnings Call. Today, we issued a press release reporting Q1 results. The earnings press release and presentation are available at amniel.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions, are forward-looking statements that are based solely on information that is now available to us. We see this section entitled Cautionary Statements on Forward-Looking Statements for factors that may impact future performance. We also discussed non-GAAP measures. Information on use of these measures and reconciliations to GAAP are in the earnings release and presentation. On the call today are Chirag and Shintu Patel, co-founders and co-CEOs. Tasos Conidera, CFO. Our commercial leaders, Andy Boyer for Affordable Medicines, Joe Renda for Specialty, and Jason Daly, Chief Legal Officer. I will now hand the call over to Chirag. Thank you, Tony. Good morning, everyone. In Q1, we delivered another quarter of strong performance and continued growth, driven by the successful execution of our strategy. Q1 revenues of $695 million grew 5% and adjusted EBITDA of $170 million grew 12%. Over the years, we have made deliberate decisions and investments across our business. and delivered on our commitments. Over time and through market cycles, we have differentiated MNIL from our peers by delivering sustainable growth, driven by our leadership in quality, innovation, and execution. Today, MNIL is in as strong a position as ever. We are emb...